IVIG, successfully employed in a variety of autoimmune disorders, such as Kawasaki disease and idiopathic thrombocytopenic purpura, has been explored as a treatment for aPL-positive patients (Lam, Brown & Sharma, 2023; Li et al., 2023). The gene discussed is FASLG; the disease is autoimmune thrombocytopenic purpura.